LGM
NXTC icon

Logos Global Management’s NextCure NXTC Stock Holding History

Logos Global Management’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-208,333
Closed -$3.42M – 65
2024
Q3 		$3.42M Hold
208,333
– – 0.37% 47
2024
Q2 		$3.98M Buy
208,333
+47,916
+30% +$932K 0.32% 48
2024
Q1 		$4.29M Buy
+160,417
New +$2.76M 0.35% 48

Other funds holding NXTC

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Logos Global Management's NXTC Position: Q4 2024 in Review

Logos Global Management sold out of NextCure (NXTC) in Q4 2024, closing a stake of 208,333 shares — an estimated $3.42M sold.

Logos Global Management first reported a position in NXTC in Q1 2024 and held it in 3 quarters. The position peaked at $4.29M in Q1 2024. 45 funds tracked by Wall St. Rank hold NXTC as of Q4 2024.

  • Logos Global Management reported no remaining NextCure position as of Q4 2024 after selling out during the quarter.
  • Logos Global Management sold 208,333 NextCure shares in Q4 2024, an estimated $3.42M.
  • Logos Global Management first reported a position in NextCure in Q1 2024 and held it in 3 quarters.
  • Logos Global Management's NextCure position peaked at $4.29M in Q1 2024.
  • 45 funds tracked by Wall St. Rank held NextCure as of Q4 2024.

Based on Logos Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.